Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield
C F
CF
Transplantation Service, St Francis Regional Medical Center, Wichita, Kansas.
D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000276:immunology* / Q000627:therapeutic use*; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D013256:Steroids